US Patent Issued to SCIENCONS AS on May 13 for "Complex comprising a PSMA-targeting compound linked to a lead or thorium radionuclide" (Norwegian Inventor)

ALEXANDRIA, Va., June 12 -- United States Patent no. 12,297,218, issued on May 13, was assigned to SCIENCONS AS (Oslo, Norway).

"Complex comprising a PSMA-targeting compound linked to a lead or thorium radionuclide" was invented by Roy Hartvig Larsen (Oslo, Norway).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to complexes comprising a prostate-specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212Pb or 227Th, through a TCMC or DOTA chelating moiety. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual...